SCHEMBL30795035

SCHEMBL30795035

COc1cccc(CC(=O)Nc2ccc(NCc3ccc(Cl)s3)cc2Cl)c1

nearest known ligand 0.55

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.55
LMNA P02545 1/20 0.55
POLB P06746 2/20 0.48
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
ALDH1A1 P00352 2/20 0.46
KDM4E B2RXH2 1/20 0.46
RAB9A P51151 1/20 0.46
USP2 O75604 1/20 0.45
CSNK1D P48730 1/20 0.45
GLS O94925 1/20 0.45
KCNQ2 O43526 1/20 0.45
GAA P10253 1/20 0.45
HIF1A Q16665 1/20 0.44
PRKACA P17612 3/20 0.44
ROCK1 Q13464 3/20 0.44
MAPK8 P45983 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2072304 1.00 MAPT (0.55) MAPTLMNAPOLBMEN1KMT2A
SCHEMBL2069717 0.89 CA12 (0.55) MAPTLMNAPOLBMEN1KMT2A
SCHEMBL30795880 0.89 CA12 (0.55) MAPTLMNAPOLBMEN1KMT2A
SCHEMBL30795130 0.86 MEN1 (0.66) MAPTLMNAPOLBMEN1KMT2A
SCHEMBL2071329 0.86 MEN1 (0.66) MAPTLMNAPOLBMEN1KMT2A
SCHEMBL30795966 0.82 MEN1 (0.53) MAPTLMNAPOLBMEN1KMT2A
SCHEMBL2069764 0.82 MEN1 (0.53) MAPTLMNAPOLBMEN1KMT2A
SCHEMBL2070087 0.81 MAPT (0.54) MAPTLMNAPOLBALDH1A1KDM4E
SCHEMBL30794683 0.81 MAPT (0.54) MAPTLMNAPOLBALDH1A1KDM4E
SCHEMBL2069253 0.80 CA12 (0.53) MAPTPOLBMEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4584250-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS Biohaven Therapeutics Ltd. (VG) 2025-07-16 EP disclosed
EP-4580679-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS Biohaven Therapeutics Ltd. (VG) 2025-07-09 EP disclosed
WO-2024054811-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS BIOHAVEN THERAPEUTICS LTD. (VG) 2024-03-14 WO disclosed
WO-2024054807-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS BIOHAVEN THERAPEUTICS LTD. (VG) 2024-03-14 WO disclosed
WO-2024050389-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS BIOHAVEN THERAPEUTICS LTD. (VG) 2024-03-07 WO disclosed